Loading
SCWorx Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SHEFTS MARK, was filed 10 Aug 2020.
SCWorx Corp.: what insiders have been doing
SCWorx Corp. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at SCWorx Corp. has published a filing in the past twelve months. The most recent one dates from 16 May 2024.
Over the whole record (from 2018), the tally stands at 8 purchases and 22 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 2.9 m USD and net income at -4.4 m USD.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
67
Thresholds
n/a
Buy Volume
€104,731
8 ops. · all time
Sell Volume
€921,288
22 ops. · all time
Since the insiders bought
- -14.0%Entry US$22,674.60 · Close at T+365 US$19,494.00
- -20.2%Entry US$24,624.00 · Close at T+365 US$19,656.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.68
Analyst consensus
Income statement
RevenueUS$2.9M
Gross profitUS$919.7k32% margin
EBITDA-US$1.5M-51% margin
Net income-US$4.4M-80.5% margin
Valuation
P/Book0.0x
Beta1.29
Balance sheet & cash
Market capUS$1.4M
Total debtUS$1.5k
Free Cash Flow-US$1.6M
Debt / Equity2%
Profitability & ownership
ROE-38.1%
ROA-5.1%
% insiders10.3%
% institutions0.0%
Last declaration on 16 May 2024
Declarations67 total
6,667 shares0Restricted Stock UnitsSEC:0001213900-24-044138:1
6,667 shares0Restricted Stock UnitsSEC:0001213900-24-044138:2
6,000 shares0Restricted Stock UnitsSEC:0001213900-24-044137:1
7,333 shares0Restricted Stock UnitsSEC:0001213900-24-044137:2
3,056 shares0Restricted Stock UnitsSEC:0001213900-24-044139:0
2,778 shares0Restricted Stock UnitsSEC:0001213900-24-044137:0
6,667 shares0Restricted Stock UnitsSEC:0001213900-24-044138:0
120,000 shares0Restricted Stock UnitsSEC:0001213900-23-029073:0
110,000 shares0Restricted Stock UnitsSEC:0001213900-23-029071:0
110,000 shares0Restricted Stock UnitsSEC:0001213900-23-029072:0
41,667 shares0Restricted Stock UnitsSEC:0001213900-21-051581:0
41,667 shares0Restricted Stock UnitsSEC:0001213900-21-051586:0
36,000 shares0Restricted Stock UnitsSEC:0001213900-21-051589:0
90,000 shares0Restricted Stock UnitsSEC:0001213900-21-051584:0
11,100 shares@ US$3.1010.9% of flowCommon StockSEC:0001213900-21-044104:1
10,900 shares@ US$3.1110.8% of flowCommon StockSEC:0001213900-21-044104:2
4,100 shares@ US$3.124.1% of flowCommon StockSEC:0001213900-21-044104:3
900 shares@ US$3.130.9% of flowCommon StockSEC:0001213900-21-044104:4
16,500 shares@ US$3.1416.5% of flowCommon StockSEC:0001213900-21-044104:5
9,900 shares@ US$3.159.9% of flowCommon StockSEC:0001213900-21-044104:6
25,100 shares@ US$3.1625.2% of flowCommon StockSEC:0001213900-21-044104:7
20,000 shares@ US$3.2020.3% of flowCommon StockSEC:0001213900-21-044104:8
1,500 shares@ US$3.07100.0% of flowCommon StockSEC:0001213900-21-044104:0
50,000 shares@ US$4.2065.4% of flowCommon StockSEC:0001213900-21-041707:0
50,000 shares@ US$2.2534.6% of flowCommon StockSEC:0001213900-21-040597:0
25 of 67 declarations
About SCWorx Corp.
SCWorx Corp. (ticker: WORX) is a United States-based company listed on the Nasdaq market, and it operates in the healthcare technology segment. The company provides data-content and data-services solutions focused on repairing, normalizing, and improving interoperability across healthcare information systems. Its core offering is a software-as-a-service platform built around an advanced attributed virtualized item data warehouse, which SCWorx says is enhanced with machine learning and artificial intelligence to support healthcare providers with better data quality, benchmarking, reporting, cost control, and operational efficiency. ([nasdaq.com](https://www.nasdaq.com/press-release/scworx-announces-compliance-nasdaqs-periodic-reporting-listing-standard-2024-11-20))
From a corporate history perspective, SCWorx is a relatively small, development-stage public company rather than a mature scaled software platform. Its SEC filings indicate an ongoing effort to broaden the product set, attract new customers, and improve monetization of its healthcare data capabilities. The company’s business address is in New York, reflecting a U.S. operating footprint and a headquarters presence in one of the key financial and commercial centers in the country. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1674227/000121390024028666/0001213900-24-028666-index.html?utm_source=openai))
Read moreShow less
SCWorx competes in a niche but strategically important part of healthcare IT: the management, accuracy, and interoperability of item and clinical data used by hospitals and other providers. Its competitive position is that of a specialized small-cap vendor, with a value proposition centered on cost savings, process automation, and improved reporting accuracy rather than broad enterprise healthcare software coverage. In that sense, it is more of a focused infrastructure provider than a generalist healthcare technology platform. ([nasdaq.com](https://www.nasdaq.com/press-release/scworx-announces-compliance-nasdaqs-periodic-reporting-listing-standard-2024-11-20))
Its principal business lines are concentrated on healthcare data services and SaaS-based software tools, not on pharmaceuticals, medical devices, or direct clinical services. This focus makes the company’s commercial story relatively clear, but also leaves it exposed to customer concentration, contract timing, and the pace of adoption inside hospital systems. The company’s own disclosures show that management continues to look for new products and additional revenue sources to support growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1674227/000121390026037303/ea0281680-10k_scworx.htm))
Recent developments have been notable for investors. The latest annual filing reported a revenue decline in 2025 and disclosed senior secured convertible notes backed by substantially all company assets, highlighting a leveraged and potentially dilutive capital structure. SCWorx also disclosed Nasdaq minimum bid price compliance issues, with an extension granted until April 6, 2026 and the potential need for a reverse stock split if the share price does not recover. Earlier Nasdaq communications confirmed that periodic reporting deficiencies had been cured and that the stock continued trading on Nasdaq, but the more recent bid-price notice underscores the company’s elevated micro-cap risk profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1674227/000121390026037303/ea0281680-10k_scworx.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
